Founded: 2025
Founders: Othman Al Musaimi, Daryl Williams
CEO: TBC
Orthogonal Peptides is dedicated to discovering, developing, manufacturing and formulating transformational cyclical and conjugate peptide therapies for patients through the fastest, most sustainable, and cost-effective synthesis and manufacturing methods
A patented separation technology development improves the manufacture of peptide therapeutic drugs. A second patented platform technology delivers a unique method for peptide synthesis which is a major advance on current synthesis approaches. It is especially powerful way to create new peptide drugs which are in cyclic forms which are essential for oral drug delivery.
Media:
Orthogonal Peptides were awarded the 2024 Emerging Tech Award by the Royal Society of Chemistry.
https://www.imperial.ac.uk/news/267673/new-imperial-spinout-developing-breakthrough-drugs